A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib
Status:
Completed
Trial end date:
2016-10-09
Target enrollment:
Participant gender:
Summary
This is a phase 1 study to describe the plasma pharmacokinetics of a single oral 75mg dose of
palbociclib administered to healthy volunteers, and subjects with mild, moderate, and
severely impaired hepatic function.